Annual Total Long Term Liabilities
$92.60 M
+$9.92 M+12.00%
31 December 2023
Summary:
Rigel Pharmaceuticals annual total long term liabilities is currently $92.60 million, with the most recent change of +$9.92 million (+12.00%) on 31 December 2023. During the last 3 years, it has risen by +$57.09 million (+160.77%). RIGL annual total long term liabilities is now at all-time high.RIGL Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Long Term Liabilities
$99.74 M
+$70.00 K+0.07%
30 September 2024
Summary:
Rigel Pharmaceuticals quarterly total long term liabilities is currently $99.74 million, with the most recent change of +$70.00 thousand (+0.07%) on 30 September 2024. Over the past year, it has increased by +$858.00 thousand (+0.87%). RIGL quarterly long term liabilities is now -2.55% below its all-time high of $102.35 million, reached on 31 March 2023.RIGL Quarterly Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RIGL Long Term Liabilities Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +12.0% | +0.9% |
| 3 y3 years | +160.8% | +28.6% |
| 5 y5 years | +6081.7% | +77.7% |
RIGL Long Term Liabilities High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +160.8% | -2.5% | +35.9% |
| 5 y | 5 years | at high | +6081.7% | -2.5% | +196.0% |
| alltime | all time | at high | >+9999.0% | -2.5% |
Rigel Pharmaceuticals Long Term Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $99.74 M(+0.1%) |
| June 2024 | - | $99.67 M(+17.3%) |
| Mar 2024 | - | $84.99 M(-8.2%) |
| Dec 2023 | $92.60 M(+12.0%) | $92.60 M(-6.4%) |
| Sept 2023 | - | $98.89 M(-2.3%) |
| June 2023 | - | $101.18 M(-1.1%) |
| Mar 2023 | - | $102.35 M(+23.8%) |
| Dec 2022 | $82.68 M(+12.6%) | $82.68 M(-6.2%) |
| Sept 2022 | - | $88.18 M(+14.9%) |
| June 2022 | - | $76.72 M(-7.6%) |
| Mar 2022 | - | $83.05 M(+13.1%) |
| Dec 2021 | $73.40 M(+106.7%) | $73.40 M(-5.4%) |
| Sept 2021 | - | $77.57 M(+4.9%) |
| June 2021 | - | $73.94 M(-13.7%) |
| Mar 2021 | - | $85.67 M(+141.3%) |
| Dec 2020 | $35.51 M(-0.1%) | $35.51 M(-6.3%) |
| Sept 2020 | - | $37.91 M(-5.4%) |
| June 2020 | - | $40.06 M(+18.9%) |
| Mar 2020 | - | $33.69 M(-5.2%) |
| Dec 2019 | $35.54 M(+2272.6%) | $35.54 M(-36.7%) |
| Sept 2019 | - | $56.14 M(+13.5%) |
| June 2019 | - | $49.49 M(-3.6%) |
| Mar 2019 | - | $51.33 M(+3326.6%) |
| Dec 2018 | $1.50 M(+1070.3%) | $1.50 M(>+9900.0%) |
| Sept 2018 | - | $0.00(-100.0%) |
| June 2018 | - | $287.00 K(+32.9%) |
| Mar 2018 | - | $216.00 K(+68.8%) |
| Dec 2017 | $128.00 K(-75.3%) | $128.00 K(+66.2%) |
| Sept 2017 | - | $77.00 K(>+9900.0%) |
| June 2017 | - | $0.00(0.0%) |
| Mar 2017 | - | $0.00(-100.0%) |
| Dec 2016 | $519.00 K(-92.1%) | $519.00 K(-74.9%) |
| Sept 2016 | - | $2.07 M(-42.6%) |
| June 2016 | - | $3.60 M(-29.7%) |
| Mar 2016 | - | $5.12 M(-22.1%) |
| Dec 2015 | $6.57 M(-44.6%) | $6.57 M(-17.1%) |
| Sept 2015 | - | $7.93 M(-39.2%) |
| June 2015 | - | $13.03 M(-32.1%) |
| Mar 2015 | - | $19.19 M(+61.8%) |
| Dec 2014 | $11.86 M(+57.9%) | $11.86 M(+92.3%) |
| Sept 2014 | - | $6.17 M(-7.0%) |
| June 2014 | - | $6.63 M(-6.6%) |
| Mar 2014 | - | $7.10 M(-5.5%) |
| Dec 2013 | $7.51 M(-14.1%) | $7.51 M(-4.1%) |
| Sept 2013 | - | $7.83 M(-3.9%) |
| June 2013 | - | $8.15 M(-3.8%) |
| Mar 2013 | - | $8.47 M(-3.1%) |
| Dec 2012 | $8.74 M | $8.74 M(-2.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2012 | - | $8.93 M(-2.0%) |
| June 2012 | - | $9.11 M(-2.0%) |
| Mar 2012 | - | $9.29 M(-1.5%) |
| Dec 2011 | $9.43 M(+2.1%) | $9.43 M(-0.5%) |
| Sept 2011 | - | $9.48 M(+0.9%) |
| June 2011 | - | $9.40 M(+0.9%) |
| Mar 2011 | - | $9.32 M(+0.8%) |
| Dec 2010 | $9.24 M(-29.5%) | $9.24 M(+0.7%) |
| June 2010 | - | $9.18 M(-0.4%) |
| Mar 2010 | - | $9.21 M(-29.7%) |
| Dec 2009 | $13.10 M(-15.7%) | $13.10 M(-4.2%) |
| Sept 2009 | - | $13.68 M(-20.2%) |
| June 2009 | - | $17.14 M(-1.2%) |
| Mar 2009 | - | $17.36 M(+11.7%) |
| Dec 2008 | $15.54 M(-11.2%) | $15.54 M(+0.3%) |
| Sept 2008 | - | $15.50 M(-3.8%) |
| June 2008 | - | $16.11 M(-3.3%) |
| Mar 2008 | - | $16.66 M(-4.8%) |
| Dec 2007 | $17.50 M(+18.4%) | $17.50 M(+1.5%) |
| Sept 2007 | - | $17.24 M(+4.2%) |
| June 2007 | - | $16.54 M(+4.9%) |
| Mar 2007 | - | $15.76 M(+6.7%) |
| Dec 2006 | $14.77 M(-4.3%) | $14.77 M(+4.0%) |
| Sept 2006 | - | $14.21 M(+8.2%) |
| June 2006 | - | $13.13 M(-9.4%) |
| Mar 2006 | - | $14.50 M(-6.1%) |
| Dec 2005 | $15.43 M(+2.2%) | $15.43 M(-9.2%) |
| Sept 2005 | - | $17.00 M(-9.8%) |
| June 2005 | - | $18.85 M(-9.0%) |
| Mar 2005 | - | $20.73 M(+37.2%) |
| Dec 2004 | $15.10 M(+101.5%) | $15.10 M(+41.3%) |
| Sept 2004 | - | $10.69 M(+14.7%) |
| June 2004 | - | $9.32 M(+12.2%) |
| Mar 2004 | - | $8.30 M(+10.8%) |
| Dec 2003 | $7.50 M(+65.5%) | $7.50 M(+11.5%) |
| Sept 2003 | - | $6.72 M(+17.5%) |
| June 2003 | - | $5.72 M(+20.4%) |
| Mar 2003 | - | $4.75 M(+4.9%) |
| Dec 2002 | $4.53 M(-38.3%) | $4.53 M(-4.7%) |
| Sept 2002 | - | $4.75 M(-9.1%) |
| June 2002 | - | $5.23 M(-16.5%) |
| Mar 2002 | - | $6.27 M(-14.7%) |
| Dec 2001 | $7.34 M(+2.1%) | $7.34 M(-13.8%) |
| Sept 2001 | - | $8.52 M(+21.7%) |
| June 2001 | - | $7.00 M(+1.9%) |
| Mar 2001 | - | $6.87 M(-4.5%) |
| Dec 2000 | $7.20 M(+4.4%) | $7.20 M |
| Dec 1999 | $6.89 M | - |
FAQ
- What is Rigel Pharmaceuticals annual total long term liabilities?
- What is the all time high annual total long term liabilities for Rigel Pharmaceuticals?
- What is Rigel Pharmaceuticals annual total long term liabilities year-on-year change?
- What is Rigel Pharmaceuticals quarterly total long term liabilities?
- What is the all time high quarterly long term liabilities for Rigel Pharmaceuticals?
- What is Rigel Pharmaceuticals quarterly long term liabilities year-on-year change?
What is Rigel Pharmaceuticals annual total long term liabilities?
The current annual total long term liabilities of RIGL is $92.60 M
What is the all time high annual total long term liabilities for Rigel Pharmaceuticals?
Rigel Pharmaceuticals all-time high annual total long term liabilities is $92.60 M
What is Rigel Pharmaceuticals annual total long term liabilities year-on-year change?
Over the past year, RIGL annual total long term liabilities has changed by +$9.92 M (+12.00%)
What is Rigel Pharmaceuticals quarterly total long term liabilities?
The current quarterly long term liabilities of RIGL is $99.74 M
What is the all time high quarterly long term liabilities for Rigel Pharmaceuticals?
Rigel Pharmaceuticals all-time high quarterly total long term liabilities is $102.35 M
What is Rigel Pharmaceuticals quarterly long term liabilities year-on-year change?
Over the past year, RIGL quarterly total long term liabilities has changed by +$858.00 K (+0.87%)